LabCorp chief medical officer Dr. Mark Brecher said, "We are excited to expand our relationship with Bristol-Myers Squibb to provide a more flexible and integrated approach to laboratory testing services in support of their innovative clinical development pipeline."
Earlier, Bristol-Myers’ early and late-stage clinical development programs were supported by LabCorp’s global central lab, biomarker and specialty testing capabilities.